Eisai: Domestic Sales of Aricept Down 6% on Volume Basis, to Target 90 Billion Yen through Patient Campaign

While domestic sales of the Alzheimer dementia (AD) treatment Aricept (donepezil) decreased 23.9% to 21.7 billion yen in Eisai’s consolidated settlement of accounts for April to June 2012, the decrease has been limited to some 6% on a volume basis...read more